Decorating The 'Christmas Tree’: US House Bills That Could Be Tacked Onto FDA User Fee Legislation

 
• By Sue Sutter

Measures aimed at spurring biomedical innovation, ensuring fewer roadblocks to development of biosimilars and generics, and strengthening the FDA’s interactions with rare disease patients could find their way into must-pass legislation reauthorizing the human drug and biologic user fee programs by 30 September.

Christmas tree ornaments
Like ornaments on the yuletide evergreen, lawmakers are eager to attach their bills to legislation reauthorizing the FDA's user fee programs. • Source: Alamy

More from User Fees

More from Pathways & Standards